Paul Peter Tak, M.D., Ph.D., FMedSci
2023
In 2023, Paul Peter Tak, M.D., Ph.D., FMedSci earned a total compensation of $1.5M as Chief Executive Officer at Candel Therapeutics, a 20% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $134,000 |
|---|---|
| Option Awards | $189,558 |
| Salary | $670,000 |
| Stock Awards | $176,506 |
| Other | $314,695 |
| Total | $1,484,759 |
FMedSci received $670K in salary, accounting for 45% of the total pay in 2023.
FMedSci also received $134K in non-equity incentive plan, $189.6K in option awards, $176.5K in stock awards and $314.7K in other compensation.
Rankings
In 2023, Paul Peter Tak, M.D., Ph.D., FMedSci's compensation ranked 777th out of 2,773 executives tracked by ExecPay. In other words, FMedSci earned more than 72.0% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 777 out of 2,773 | 72nd |
Division Manufacturing | 461 out of 1,516 | 70th |
Major group Chemicals And Allied Products | 316 out of 855 | 63rd |
Industry group Drugs | 308 out of 821 | 63rd |
Industry Biological Products, Except Diagnostic Substances | 99 out of 204 | 52nd |
Source: SEC filing on May 30, 2024.
FMedSci's colleagues
We found two more compensation records of executives who worked with Paul Peter Tak, M.D., Ph.D., FMedSci at Candel Therapeutics in 2023.